

Original articles:

1. Changes in hepatic tissue water content in EC-, UW-, and HTK-preserved livers tested in a pig liver transplant model
R. Steininger, E. Roth, P. Holzmüller, H. Reckendorfer, M. Sperlich, **T. Gruenberger**, E. Moser, F. Mühlbacher
Transplantation Proceedings 1991; 23(5): 2414
2. Comparison of HTK- and UW- solution for liver preservation tested in an old model in the pig
R. Steininger, E. Roth, P. Holzmüller, H. Reckendorfer, **T. Gruenberger**, M. Sperlich, H. Burgmann, E. Moser, W. Feigl, M. Mühlbacher
Transplant International 1992; 5: 403
3. The impact of donor age on graft function in living related kidney transplantation
F. Längle, T. Sautner, **T. Gruenberger**, P. Götzinger, F. Mühlbacher
Transplantation Proceedings 1992; 24(6): 2725
4. Die UW-Lösung in der Organkonservierung für die orthotope Lebertransplantation
R. Steininger, F. Mühlbacher, E. Roth, **T. Gruenberger**, P. Götzinger, P. Wamser, F. Längle, H. Reckendorfer, M. Sperlich
Acta Chirurgica Austriaca 1992; 24: 231-236
5. Impact of vesicoureteral reflux on graft survival in renal transplantation
T. Gruenberger, M. Gnant, T. Sautner, K. Höberth, R. Steininger, J. Hofbauer, F. Mühlbacher
Transplantation Proceedings 1993; 25(1): 1058
6. Impact of donor criteria on postoperative graft function in liver transplantation
Th. Gruenberger, R. Steininger, M. Mittlböck, Th. Sautner, P. Wamser, F. Mühlbacher
Transplantation Proceedings 1993; 25(6): 3156

7. Value of serum soluble tumour necrosis factor concentration in the diagnosis and prognosis of renal graft rejection
M. Keil, MK. Pec, G. Schenn, **Th. Gruenberger**, G. Kramer,
R. Függer, R. Steininger, F. Mühlbacher, P. Balke, F. Stockenhuber
Nephro Dial Transplant 1994; 9(7): 815-819
8. Andrologic status before and after liver transplantation
S. Madersbacher, **Th. Gruenberger**, U. Maier
J. of Urology 1994; 151(5): 1251-4
9. L-Arginine deficiency after liver transplantation as an effect of arginase efflux from the graft; influence on nitric oxide metabolism
E. Roth, R. Steininger, S. Winkler, F. Längle, **Th. Gruenberger**,
R. Függer, F. Mühlbacher
Transplantation 1994; 57(5): 665
10. Transhepatic metabolism of TNF- α , IL-6 and Endotoxin in the early hepatic reperfusion period after human liver transplantation
R. Steininger, E. Roth, R. Függer, S. Winkler, F. Längle,
Th. Gruenberger, P. Götzinger, F. Mühlbacher
Transplantation 1994, 58(2): 179-83
11. Influence of donor criteria on postoperative graft function after oLTX
Th. Gruenberger, R. Steininger, Th. Sautner, M. Mittlböck,
F. Mühlbacher
Transplant International 1994; 7(Supp1): 672
12. Kann man einer hochselektionierten Patientinnengruppe nach brusterhaltender Therapie wegen Mammakarzinoms die postoperative Nachbestrahlung ersparen?
Th. Gruenberger, M. Gorlitzer, Th. Soliman, M. Rudas,
M. Mittlböck, P. Götzinger, M. Gnant, A. Reiner, B. Teleky,
W. Seitz, R. Jakesz
Acta Chirurgica Austriaca 1995; 27(5/6): 269-273
13. Tumor recurrence after oLTX
Th. Gruenberger, Th. Windhager, M. Gnant, M. Mittlböck,
R. Steininger, F. Herbst, F. Mühlbacher
Transplant International 1996; 9(Sup1): S151

14. Prediction of graft dysfunction by analysis of liver biopsies after cold storage
Th. Gruenberger, S. Winkler, F. Garro, M. Barlan, W. Huber, E. Roth, R. Steininger, F. Mühlbacher
Transplant International 1996; 9(Sup1): S132
15. The impact of liver transplantation on endocrine status in men
St. Madersbacher, G. Ludvik, Th. Stulnig, **Th. Gruenberger**, U. Maier
Clinical Endocrinology 1996; 44: 461-466
16. Improvement of cardiac output and liver blood flow and reduction of pulmonary vascular resistance by intravenous infusion of L-Arginine during the early reperfusion period in pig liver transplantation
F. Längle, R. Steininger, E. Waldmann, **Th. Gruenberger**, H. Benditte, M. Mittlböck, Th. Soliman, M. Schindl, U. Windberger, F. Mühlbacher, E. Roth
Transplantation 1997; 63: 1225-1233
17. Late ureteral obstruction after kidney transplantation
U. Maier, S. Madersbacher, S. Banyai-Falger, M. Susani, **Th. Gruenberger**
Transplant International 1997; 10: 65-68
18. Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients
R. Jakesz, H. Salmonigg, M. Gnant, E. Kubista, P. Steindorfer, H. Hausmaninger, P. Sevela, B. Tschurtschenthaler, M. Fridrik, M. Stierer, R. Kolb, G. Steger and the **Austrian Breast Cancer Study Group**
European Journal of Cancer 1998; 34/1: 66-70
19. It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer patients
Th. Gruenberger, M. Gorlitzer, T. Soliman, M. Rudas, M. Mittlböck, M. Gnant, A. Reiner, B. Teleky, Seitz, R. Jakesz
Breast Cancer Research and Treatment 1998; 50: 37-46
20. Liver resection and transplantation - therapeutic concepts in surgical treatment of hepatic metastases
R. Steininger, **Th. Gruenberger**
Acta Chirurgica Austriaca 1998; 30: 206-210

21. Preservation of the liver- is it possible to extend the time of storage?
H. Pokorny, **Th. Gruenberger**, S. Rockenschaub, H. Puhalla, F. Mühlbacher, R. Steininger
Transplantation Proceedings 1999; 31/5: 2074-76
22. First experiences with mesh wrapping for parenchymal liver injuries in orthotopic liver transplantation (OLT)
Th. Soliman, H. Pokorny, S. Rockenschaub, H. Puhalla, **T. Gruenberger**, M. Schindl, F. Längle, G. Berlakovich, F. Mühlbacher, R. Steininger
Transplantation Proceedings 1999; 31(1-2): 538-9
23. Immunomodulated effects of glycine in LPS-treated monocytes: reduced TNF- α production and accelerated IL-10 expression
A. Spittler, CM. Reissner, R. Oehler, A. Gornikiewicz, **Th. Gruenberger**, N. Manhart, T. Brodowicz, M. Mittlboeck, G. Boltz-Nitulescu, E. Roth
FASEB Journal 1999; 13: 563-571
24. Randomized trial of low-dose chemotherapy added to Tamoxifen in patients with receptor-positive and lymph node-positive breast cancer
R. Jakesz, H. Hausmaninger, K. Haider, E. Kubista, H. Salmonigg, M. Gnant, D. Manfreda, G. Tschurtschenthaler, R. Kolb, M. Stierer, M. Fridrik, B. Mlineritsch, P. Steindorfer, M. Mittlboeck, G. Steger, and **the Austrian Breast Cancer Study Group**
Journal of Clinical Oncology 1999; 17/6: 1701-1709
25. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
E. Kucera, P. Speiser, M. Gnant, L. Szabo, H. Samonigg, H. Hausmaninger, M. Mittlboeck, M. Fridrik, M. Seifert, E. Kubista, A. Reiner, R. Zeillinger, R. Jakesz and **the Austrian Breast Cancer Study Group**
European Journal of Cancer 1999; 35/3: 398-405
26. Management of organ donation following trauma in conventional heart-beating donor and non-heart-beating donor situations
H. Pokorny, H. Puhalla, CG. Krenn, T. Soliman, F. Langer, **Th. Gruenberger**, B. Gollackner, M. Schindl, P. Wamser, P. Goetzinger, T. Sautner, MF. Gnant, R. Steininger, F. Muehlbacher
Trauma Care 1999; 9/1: 30-32

27. Organ survival after primary dysfunction of liver grafts in clinical oLT
H. Pokorny, **Th. Gruenberger**, T. Soliman, S. Rockenschaub, F. Längle, R. Steininger
Transplant International, 2000;13 Suppl 1:S154-7
28. Parenchymal liver injuries in orthotopic liver transplantation
T. Soliman, F. Langer, H. Puhalla, H. Pokorny, **Th. Gruenberger**,
G.A. Berlakovich, R. Steininger and F. Mühlbacher
Transplantation 2000;69(10):2079-84
29. Echogenicity of liver metastases is an independent prognostic factor
after potentially curative treatment
Th. Gruenberger, JL. Jourdan, J. Zhao, J. King, DL. Morris
Archives of Surgery 2000; 135(11): 1285-90
30. Reduction in recurrence risk for involved or inadequate margins with
edge cryotherapy after liver resection for colorectal metastases
Th. Gruenberger, JL. Jourdan, J. Zhao, J. King, DL. Morris
Arch Surg. 2001 Oct;136(10):1154-7
31. Extending the limits for curative liver resections by portal vein
embolisation
KS. Haghghi, D. Glenn, **Th. Gruenberger**, DL. Morris
Int Surg. 2009 Jan-Feb;94(1):43-7.
32. Echogenicity of liver metastases from colorectal carcinoma is an
independent prognostic factor in patients treated with regional
chemotherapy
Gruenberger T, Zhao J, King J, Chung T, Clingan PR, Morris DL
Cancer 2002 Mar 15;94(6):1753-9
33. Long-term follow-up of surgically treated gallbladder cancer patients
Puhalla H, Wild T, Bareck E, Pokorny H, Ploner M, Soliman T, Stremitzer S,
Depisch D, Laengle F, **Gruenberger T**
Eur J Surg Oncol 2002 Dec;28(8):857-63
34. Staged treatment of bilobar hepatic metastases from colorectal
cancer
Th. Gruenberger, DL. Morris
Eur J Surg. 2002;168(8-9):516-8

35. Alternative regional treatment of resectable and unresectable liver metastases
Th. Gruenberger
Eur Surg 2002,34/6, 337-40
36. Current strategies in the treatment of colorectal cancer liver metastases: aspects of surgical treatment
M. Schindl, **Th. Gruenberger**, F. Längle
Eur Surg 2002, 34/6, 332-6
37. Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: Pilot study in patients with hepatocellular carcinoma
Morris DL, Jourdan JL, Finlay I, **Gruenberger T**, The MP, Pourgholami MH
Int J Oncol 2002 Oct;21(4):901-6
38. Resection of Hilar Cholangiocarcinomas: Pivotal Prognostic Factors and Impact of Tumor Sclerosis
Puhalla H, **Gruenberger T**, Pokorny H, Soliman T, Wrba F, Sponer U, Winkler T, Ploner M, Raderer M, Steininger R, Mühlbacher F, Laengle F
World J Surg 2003; 27/6: 680-4
39. Mitomycin C in combination with capecitabine or biweekly high dose gemcitabine in patients with advanced biliary tract cancer: a randomized phase II trial
Kornek GV, Schuell B, Laengle F, **Gruenberger T**, Penz M, Karall K, Depisch D, Lang F, Scheithauer W
Ann Oncology 2004, 15, 478-83
40. p53 analyses in gallbladder cancer: comparison of gene analysis versus immunohistochemistry
Puhalla H, Kandioler D, Ludwig C, Filipits M, Wrba F, Laengle F, Jakesz R, **Gruenberger T**
Anticancer Research, 2004, 24, 1201-6
41. Changes in liver surgery for colorectal cancer liver metastases under neoadjuvant treatment strategies
Th. Gruenberger, B. Schuell, H. Puhalla, E. Schwanzer, M. Bodingbauer, F. Laengle, G. Kornek, W. Scheithauer
European Surgery 2004, 36/5; 317-21

42. Anforderungen der Chirurgie an die bildgebende Diagnostik
Th. Gruenberger
Radiologe 2004, 44; 1154-59
43. Treatment and outcome of intrahepatic cholangiocellular carcinoma
H. Puhalla, B. Schuell, H. Pokorny, GA. Kornek, W. Scheithauer, **Th. Gruenberger**
Am J Surgery 2005, 189/2; 173-7
44. Multidetector-CT (MDCT) der Leber
W. Schima, C. Kulinna, A. Ba-Ssalamah, **Th. Gruenberger**
Radiologe 2005, 45/1; 15-23
45. Influence of laparoscopy on survival after surgery for gallbladder carcinoma: a matched-pair analysis
Puhalla, H., **Gruenberger, T.**, Pokorny, H., Ploner, M., Bareck, E., Depisch, D., Zacherl, J., Bischof, G.
European Surgery 2004, 36/6; 350-55
46. Interdisciplinary management of colorectal cancer liver metastases
Th. Gruenberger, B. Gruenberger, A. Becherer, J. Kettenbach, K. Dieckmann, W. Schima
European Surgery 2006, 38/2; 107-11
47. Side effects during chemotherapy predict tumour response in advanced colorectal cancer
B. Schuell, **Th. Gruenberger**, G. Kornek, N. Dworan, D. Depisch, F. Lang, B. Schneeweiss, W. Scheithauer
Britsch Journal of Cancer 2005; 93, 744-48
48. E-Cadherin and β -Catenin expression in normal, inflamed and cancerous gallbladder tissue
H. Puhalla, B. Herberger, A. Soleiman, M. Filipits, F. Laengle, **Th. Gruenberger**, F. Wrba
Anticancer Research 2005; 25, 4249-54
49. Neoadjuvant therapy with Bevacizumab
Th. Gruenberger, B. Gruenberger, W. Scheithauer
Journal Clinical Oncology 2006; 24, 2592-93

50. HER-2/neu protein expression in colorectal cancer
B. Gruenberger, **Th. Gruenberger**, W. Scheithauer, C. Zielinski, F. Wrba
BMC Cancer 2006; 6: 123
51. Selective resection of colorectal liver metastases
D. Tamandl, B. Gruenberger, B. Herberger, S. Schoppmann, M. Bodingbauer, M. Schindl, H. Puhalla, E. Fleischmann, W. Schima, R. Jakesz, F. Laengle, **Th. Gruenberger**
Eur J Surg Oncol 2007; 33:174-82
52. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases
M. Bodingbauer, D. Tamandl, K. Schmid, C. Plank, W. Schima, **Th. Gruenberger**
Br J Surgery 2007; 94(9): 1133-8
53. Expression of p21^{Waf1/Cip1}, p57^{Kip2} and HER2/neu in Patients with Gallbladder Cancer
H Puhalla, F Wrba, D Kandioler, M Lehnert, A Huynh, **T Gruenberger**, D Tamandl, M Filipits
Anticancer Research 2007; 27(3B): 1679-84
54. Activated mTOR is an adverse prognostic factor in patients with biliary tract adenocarcinoma
B. Herberger, H. Puhalla, M. Lehnert, F. Wrba, S. Novak, A. Brandstetter, **Th. Gruenberger**, R. Pirker, M. Filipits
Clin Cancer Research 2007; 13(16): 4795-9
55. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group
B. Nordlinger, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulas V, Giuliante F, Glimelius B, Golling M, **Gruenberger T**, Tabernero J, Wasan H, Poston G; on behalf of European Colorectal Metastases Treatment Group
Eur J Cancer 2007; 43(14): 2037-45
56. Post-treatment imaging of liver tumours
W. Schima, A. Ba-Ssalamah, A. Kurturan, M. Schindl, **Th. Gruenberger**
Cancer Imaging 2007; 7: S28-S36

57. Effects of continuous remifentanyl administration on intra-operative subcutaneous tissue oxygen tension
B. Kabon, A. Kugener, **Th. Gruenberger**, M. Niedermayr, E. Fleischmann, M. Freissmuth, A. Kurz
Anaesthesia 2007; 62: 1101-9
58. Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases
D. Tamandl, B. Herberger, B. Gruenberger, S. Schoppmann, H. Puhalla, M. Schindl, W. Schima, R. Jakesz, **Th. Gruenberger**
Surgery 2008; 143(5): 648-57
59. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
B. Gruenberger, D. Tamandl, J. Schueller, W. Scheithauer, C. Zielinski, F. Herbst, **Th. Gruenberger**
Journal Clinical Oncology 2008; 26(11): 1830-5
60. Neoadjuvant Treatment of Colorectal Cancer with Bevacizumab: The Perioperative Angiogenic Balance is Sensitive to Systemic Thrombospondin-1 Levels
C. Brostjan, K. Gebhardt, B. Gruenberger, S. Roka, **Th. Gruenberger**
Clin Cancer Research 2008; 14(7): 2065-74
61. Patterns of Hepatotoxicity after Chemotherapy for Colorectal Cancer Liver Metastases
S. Kandutsch, M. Klinger, S. Hacker, F. Wrba, B. Gruenberger, **Th. Gruenberger**
Eur J Surg Oncol. 2008 Nov;34(11):1231-6. Epub 2008 Feb 12
62. Randomized study of perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983)
B. Nordlinger, H. Sorbye, B. Glimelius, GJ. Poston, P. M. Schlag, P. Rougier, W. Bechstein, JN. Primrose, ET. Walpole, M. Finch-Jones, D. Jaeck, D. Mirza, RW. Parks, L. Collette, M. Praet, U. Bethe, E. Van Cutsem, W. Scheithauer, **T. Gruenberger**
Lancet 2008; 371(9617): 1007-16

63. Using Bevacizumab and Cetuximab before liver surgery
B. Gruenberger, **Th. Gruenberger**
Current colorectal cancer reports 2008; 4: 126-9
64. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases
B. Gruenberger, W. Scheithauer, R. Punzengruber, C. Zielinski, D. Tamandl, **Th. Gruenberger**
BMC Cancer 2008; 25/8: 120
65. Consensus on the medical treatment of colon cancer
G. Kornek, W. Scheithauer, R. Anghel, G. Bodoky, F. Ciardiello, T. Ciuleanu, R. Glynne-Jones, **T. Gruenberger**, I. Koza, J. Ocvirk, L. Petruzella, G. Poston, G. Ramadori, W. Schmiegel, S. Segalier, J. Tabernero, H. Zwierzina, C. Zielinski
Magazine of European Medical Oncology 2008; 1: 79-90
66. Surgery vs surgery and chemotherapy for colorectal liver metastases
B. Nordlinger, **Th. Gruenberger**, H. Sorbye, B. Glimelius, L. Collette
Lancet 2008, 372 (9634): 203
67. Trials on preoperative chemotherapy in resectable colorectal liver metastases need prospective evaluation of predictive factors of response
Th. Gruenberger, B. Gruenberger
J Clin Oncology 2008; 26, 3813
68. Urgent Need for a New Staging System in Advanced Colorectal Cancer.
G.J. Poston, J. Figueras, F. Giuliani, G. Nuzzo, A.F. Sobrero, J.F. Gigot, B. Nordlinger, R. Adam, **T. Gruenberger**, M.A. Choti, A.J. Bilchik, E.J. Van Cutsem, J.M. Chiang, M.I. D'Angelica
Journal Clinical Oncology 2008; 26: 4828-33
69. Influence of Hepatic Resection Margin on Recurrence and Survival in Intrahepatic Cholangiocarcinoma
D. Tamandl, B. Herberger, B. Gruenberger, H. Puhalla, M. Klinger, **Th. Gruenberger**
Ann Surg Oncology 2008; 15: 2787-94

70. HB-EGF is a paracrine growth stimulator for early tumor-prestages in inflammation-associated hepatocarcinogenesis
S. Sagmeister, C. Drucker, A. Losert, M. Grusch, A. Daryabeigi, W. Parzefall, N. Rohr-Udilova, C. Bichler, B. Smedsrod, D. Kandioler, **Th. Gruenberger**, F. Wrba, R. Schulte-Hermann, B. Grasl-Kraupp
J Hepatol. 2008 Dec;49(6):955-64. Epub 2008 Oct 7.
71. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
B. Nordlinger, E. Van Cutsem, **Th. Gruenberger**, B. Glimelius, G. Poston, P. Rougier, A. Sobrero, M. Ychou on behalf of the European Colorectal Metastases Treatment Group
Ann Oncology 2009 Jun;20(6):985-92. Epub 2009 Jan 19.
72. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases
M. Klinger, S. Eipeldauer, S. Hacker, B. Herberger, D. Tamandl, M. Dorfmeister, C. Koelblinger, B. Gruenberger, **Th. Gruenberger**
Eur J Surg Oncol 2009; 35: 515-20
73. Nitrous oxide may not increase the risk of cancer recurrence after colorectal surgery: a follow-up of a randomized controlled trial
E. Fleischmann, C. Marschalek, K. Schlemitz, J. Dalton, **Th. Gruenberger**, F. Herbst, A. Kurz, D. Sessler
BMC Anaesthesiology 2009; 9:1
74. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients
D. Tamandl, B. Gruenberger, K. Kaczirek, B. Herberger, **Th. Gruenberger**
J Surg Oncol 2009; 100: 364-71
75. Endo-sponge assisted treatment of anastomotic leakage following colorectal surgery
S. Riss, A. Stiff, M. Meier, E. Haiden, **Th. Gruenberger**, M. Bergmann
Colorectal Dis. 2010 Jul;12(7 Online):e104-8. Epub 2009 Apr 13

76. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma
D. Tamandl, K. Kaczirek, B. Gruenberger, C. Koelblinger, J. Maresh, R. Jakesz, **Th. Gruenberger**
Br J Surgery 2009; 96: 919-25
77. [Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.](#)
B. Herberger, W. Berger, H. Puhalla, K. Schmid, S. Novak, A. Brandstetter, C. Pirker **Th. Gruenberger**, M. Filipits
Mol Cancer Ther. 2009 Jun;8(6):1547-56. Epub 2009 Jun 9
78. [The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.](#)
Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, **Gruenberger T**, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C
Ann Oncol. 2009 Jun;20 Suppl 7:vii1-vii6
79. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, **Gruenberger T**, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; On Behalf of the PRECISION V Investigators.
Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52. Epub 2009 Nov 12.
80. The EGF 61A/G polymorphism - a predictive marker for recurrence of liver metastases from colorectal cancer
Kovar FM, Thallinger C, Marsik CL, Perkmann T, Puhalla H, Haslacher H, Wrba F, Wagner OF, **Gruenberger T**, Endler G.
Wien Klin Wochenschr. 2009;121(19-20):638-43

81. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
Folprecht G, **Gruenberger T**, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczyński C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH.
Lancet Oncol. 2010 Jan;11(1):38-47. Epub 2009 Nov 26.
82. Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX.
Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B, **Gruenberger T**.
Ann Surg Oncol. 2010 Aug;17(8):2059-65. Epub 2010 Feb 23
83. [Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?](#)
Kulemann V, Schima W, Tamandl D, Kaczirek K, **Gruenberger T**, Wrba F, Weber M, Ba-Ssalamah A.
Eur J Radiol. 2011; 79: e1-6
84. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study
Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K, Fleischmann E, **Gruenberger T**
Ann Surg. 2010 Jul;252(1):124-30
85. Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes
Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker K, Gruenberger B, **Gruenberger T**, Kuehrer I, Schoppmann SF, Gnant M, Brostjan C
J Thromb Haemost. 2010 Aug;8(8):1809-19
86. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, **Gruenberger T**, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W,

Van de Velde C, Schmoll HJ, Sobrero A, Tabernero J
Ann Oncol. 2010 Jun;21 Suppl 6:vi1-10

87. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy
Tamandl D, Klingler M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, **Gruenberger T**
Ann Surg Oncol. 2011; 18: 421-30
88. Liver Resection for Colorectal Metastases in Presence of Extrahepatic Disease: Results from an International Multi-institutional Analysis
Pulitanò C, Bodingbauer M, Aldrighetti L, de Jong M, Parks R, Castillo F, Schulick R, Wigmore S, Choti M, Garden J, **Gruenberger T**, Pawlik T
Ann Surg Oncol. 2011; 18: 1380-8
89. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S, **Gruenberger T**
Lancet Oncology 2010; 11: 1142-8
90. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing
P. Krieger, D. Tamandl, B. Herberger, P. Faybik, E. Fleischmann, J. Maresch, **Th. Gruenberger**
Ann Surg Oncol 2011; 18: 1644-50
91. Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection
C. Politano, M. Bodingbauer, L. Aldrighetti, MA. Choti, F. Castillo, RD. Schulick, **Th. Gruenberger**, T. Pawlik
Ann Surg Oncol 2012; 19: 435-42
92. Value of the hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma
S. Stremitzer, D. Tamandl, K. Kaczirek, J. Maresch, B. Abbasov, BA Payer, A. Ferlitsch, **Th. Gruenberger**
Br J Surgery 2011; 98: 1752-8

93. Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO Position Statement on the Use of Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma
M. Peck, W. Sieghart, C. Kölblinger, M. Reiter, M. Schindl, G. Ulbrich, R. Steininger, C. Müller, R. Stauber, M. Schöniger-Hekele, M. Gschwendtner, C. Plank, M. Funovics, I. Graziadei, J. Lammer,
Th Gruenberger, G. Gastl, F. Karnel
Wien Klin Wochenschr 2012; 124: 104-10
94. [Surgery for liver metastases originating from sarcoma-case series.](#)
Zacherl M, Bernhardt GA, Zacherl J, Gruber G, Kornprat P, Bacher H, Mischinger HJ, Windhager R, Jakesz R, **Grünberger T.**
Langenbecks Arch Surg. 2011 Oct;396(7):1083-91. Epub 2011 Jul 8.
95. Comparison of lymphangiogenesis between primary colorectal cancer and corresponding liver metastases
Schoppmann A, Tamandl D, Herberger B, Längle F, Birner P, Geleff S,
Grünberger T, Schoppmann SF
Anticancer Res 2011; 31: 4605-11
96. The Role of Biological Agents in the Resection of Colorectal Liver Metastases
[Nordlinger B, Adam R, Arnold D, Zalcbberg JR, Gruenberger T](#)
[Clin Oncol \(R Coll Radiol\).](#) 2012 Aug;24(6):432-42
97. [Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients \(EORTC Intergroup Trial 40983\).](#)
Sorbye H, Mauer M, **Gruenberger T**, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Van Cutsem E, Scheithauer W, Lutz MP, Nordlinger B
Ann Surg. 2012 Mar;255(3):534-9
98. Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases
L. Vigano, L. Capussotti, E. Barroso, G. Nuzzo, C. Laurent, JN. Ijzermans, JF. Gigot, J. Figueras, **Th. Gruenberger.**, DF: Mirza, D. Elias, G. Poston, C. Letoublon, H. Isoniemi, J. Herrera, F. Castro Sousa, F. Pardo, V. Lucidi, I. Popesu, R. Adam
Ann Surg Oncol 2012; 19: 2786-96

99. Gadoteric acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histology as a standard of reference
Berger-Kulemann V, Schima W, Baroud S, Koelblinger C, Kaczirek K, **Gruenberger T**, Schindl M, Maresch J, Weber M, Ba-Ssalamah A
Eur J Surg Oncol 2012; 38: 670-6
100. Hepatic steatosis assessment with (1)H-spectroscopy and chemical shift imaging at 3.0T before hepatic surgery: reliable enough for making clinical decisions?
Koelblinger C, Krssak M, Maresch J, Wrba F, Kaczirek K, **Gruenberger T**, Tamandl D, Ba-Ssalamah A, Berger-Kulemann V, Weber M, Schima W
Eur J Radiol. 2012 Nov;81(11):2990-5
101. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including Bevacizumab
Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B, Wrba F, **Gruenberger T**.
Br J Surg. 2012 Nov;99(11):1575-82
102. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation
Starlinger P, Alidzanovic L, Schauer D, Maier T, Nemeth C, Perisanidis B, Tamandl D, Gruenberger B, **Gruenberger T**, Brostjan C.
Br J Cancer. 2012 Sep 4;107(6):961-6
103. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival
Th. Gruenberger, D. Arnold, L. Rubbia-Brandt
Surg Oncol. 2012 Dec;21(4):309-15
104. Intermediate Monocytes but Not TIE2-Expressing Monocytes are a Sensitive Diagnostic Indicator for Colorectal Cancer
D. Schauer, P. Starlinger, C. Reiter, N. Jahn, P. Zajc, E. Buchberger, T. Bachleitner-Hofmann, M. Bergmann, A. Stift, **T. Gruenberger**, C. Brostjan
PLoS One. 2012;7(9):e44450
105. Segmental and lobar administration of Irinotecan Bead leads to tumour destruction: a case-control series
Robert P. Jones, Declan Dunne, Paul Sutton, Hassan Z. Malik, Stephen W. Fenwick, Monica Terlizzo, Elizabeth O'Grady, Claus Koelblinger, Stefan Stättner, Stefan Stremitzer, **Thomas Gruenberger** and Graeme J. Poston

HPB 2013; 15/1: 71-7

106. Clinical evidence for thrombospondin-1 as a relevant suppressor of liver regeneration
Starlinger P, Schauer D, Alidzanovic L, Zikeli S, Gebhardt K, Luf F, Fleischmann E, Perisanidis B, Gruenberger B, **Gruenberger T**, Brostjan C.
J Hepatol. 2013 May;58(5):1053-4
107. Multicenter Validation Study of Pathologic Response and Tumor Thickness at the Tumor–Normal Liver Interface as Independent Predictors of Disease-Free Survival after Preoperative Chemotherapy and Surgery for Colorectal Liver Metastases
[A. Brouquet](#), [G. Zimmitti](#), [S. Kopetz](#), [J. Stift](#), [C. Julié](#), [Al. Lemaistre](#), [A. Agarwal](#), [V. Patel](#), [S. Benoist](#), [B. Nordlinger](#), [A. Gandini](#), [M. Rivoire](#), [S. Stremitzer](#), **T. Gruenberger**, [JN Vauthey](#), [DM Maru](#)
Cancer 2013; 119(15): 2778-88
108. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation
M. Scharitzer, A. Ba-Ssalamah, H. Ringl, C. Kölblinger, **T. Gruenberger**, M. Weber, W. Schima
Eur J Radiology 2013; 23(8): 2187-96
109. Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging
Wibmer A, Prusa AM, Nolz R, **Gruenberger T**, Schindl M, Ba-Ssalamah A.
Radiology. 2013 Dec;269(3):777-86
110. Peri-operative FOLFOX4 chemotherapy and surgery for resectable liver metastases from colorectal cancer: Long-term survival results of the EORTC Intergroup phase III study 40983
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, **Gruenberger T**
Lancet Oncology 2013; 14(12): 1208-15
111. Strategies to improve clinical research in surgery through international collaboration

Søreide K, Alderson D, Bergenfelz A, Beynon J, Connor S, Deckelbaum DL, Dejong CH, Earnshaw JJ, Kyamanywa P, Perez RO, Sakai Y, Winter DC; **International Research Collaboration in Surgery (IRIS) ad-hoc working group**

Lancet. 2013 Sep 28;382(9898):1140-51. doi: 10.1016/S0140-6736(13)61455-5

112. [Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans.](#)

Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, Birner P, Fleischmann E, Gruenberger B, Brostjan C, **Gruenberger T**
Hepatology. 2014 Jul;60(1):257-66. doi: 10.1002/hep.26950

113. [Role of platelets in systemic tissue protection after remote ischemic preconditioning.](#)

Starlinger P, **Gruenberger T**
Hepatology 2014; 60(4): 1136-8

114. [Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept \(CELIM study\).](#)

Folprecht G, **Gruenberger T**, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH.
Ann Oncol. 2014 May;25(5):1018-25. doi: 10.1093/annonc/mdu088.
Epub 2014 Feb 27

115. [Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983.](#)

Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, **Gruenberger T**, Schlag PM, Punt CJ, Ledermann J, Ruers TJ.
Eur J Cancer. 2014 Mar;50(5):912-9. doi: 10.1016/j.ejca.2013.12.008.
Epub 2014 Jan 7

116. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases
Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry R, Stiff J, Wrba F, **Gruenberger T**, Lenz HJ.
Cancer. 2015 Jun 1;121(11):1898-905

117. Monocytes with angiogenic potential are selectively induced by liver resection and accumulate near the site of liver regeneration
Schauer D, Starlinger P, Zajc P, Alidzanovic L, Maier T, Buchberger E, Pop L, Gruenberger B, **Gruenberger T**, Brostjan C.
BMC Immunology 2014; Oct 30;15:50. doi: 10.1186/s12865-014-0050-3
118. [Early survival and safety of ALPPS: first report of the International ALPPS Registry.](#)
Schadde E, Ardiles V, Robles-Campos R, Malago M, Machado M, Hernandez-Alejandro R, Soubrane O, Schnitzbauer AA, Raptis D, Tschuor C, Petrowsky H, De Santibanes E, Clavien PA; ALPPS Registry Group:
[Abdalla E](#), [Adam R](#), [Alden D](#), [Aldrighetti LA](#), [de Paz EA](#), [Balzan S](#), [Barkun J](#), [Björnsson B](#), [Castro-Benitez C](#), [Brustia R](#), [Chapman WC](#), [Chardarov N](#), [Chaychenko D](#), [Cherqui D](#), [Corradetti L](#), [Croome K](#), [Cugat E](#), [Dong J](#), [Donckier V](#), [Doussot A](#), [Enne M](#), [Figueras J](#), [Herrero Fonollosa E](#), [Gauzolino R](#), **Gruenberger T**, [Keutgen XM](#), [Koffron A](#), [Kukodo N](#), [Lendoire J](#), [Li J](#), [Lodge JP](#), [Logan S](#), [Lorenzin D](#), [Lucidi V](#), [Lurje G](#), [Masetti M](#), [McCormack L](#), [Montalti R](#), [Nagino M](#), [Nüssler N](#), [Ortega-Deballon P](#), [Pineda K](#), [Pissanou T](#), [Ratti F](#), [Regimbeau JM](#), [Rogiers X](#), [Sakamoto Y](#), [Sandström P](#), [Santoyo J](#), [Scatton O](#), [Sergeant G](#), [Serrablo A](#), [Sharma D](#), [Skipenko O](#), [Solomonov E](#), [Sparrelid E](#), [Stojanovic S](#), [Strassberg S](#), [Torrenga H](#), [Troisi R](#), [Truant S](#), [Vacharajani N](#), [Vianna de Carvalho E](#), [Vibert E](#), [Vicente E](#), [Vivarelli M](#), [Vyas S](#), [Wen Z](#), [Zheng W](#), [Zhou J](#).
Ann Surg. 2014 Nov;260(5):829-36; discussion 836-8
119. [B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer.](#)
Meshcheryakova A, Tamandl D, Bajna E, Stiff J, Mittlboeck M, Svoboda M, Heiden D, Stremitzer S, Jensen-Jarolim E, **Grünberger T**, Bergmann M, Mechtcheriakova D.
PLoS One. 2014 Jun 6;9(6):e99008. doi: 10.1371/journal.pone.0099008.
eCollection 2014.
120. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases
Stremitzer S, Stiff J, Graf A, Singh J, Starlinger P, Gruenberger B, Tamandl D, **Gruenberger T**
Ann Surg Oncol 2015; 22(4): 1315-23

121. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma
Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C, **Gruenberger T**, Shen J, Man K, Trauner M, Yu J, Gao CF, Mikulits W.
Int J Cancer. 2015 Jul 15;137(2):385-94
122. Reply To:
Comment on: [Serotonin in liver tumor: Friend or foe?](#)
Starlinger P, Lesurtel M, Brostjan C, Clavien PA, **Gruenberger T**.
Hepatology. 2015 Jul;62(1):319-20
123. [Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.](#)
Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R.
Ann Oncol. 2015 Apr;26(4):702-8. doi: 10.1093/annonc/mdu580
124. [Reply: To PMID 24277679.](#)
Starlinger P, Brostjan C, **Gruenberger T**.
Hepatology. 2015 Sep;62(3):984. doi: 10.1002/hep.27672.
125. [Deficiency in thrombopoietin induction after liver surgery is associated with postoperative liver dysfunction.](#)
Haegele S, Offensperger F, Pereyra D, Lahner E, Assinger A, Fleischmann E, Gruenberger B, **Gruenberger T**, Brostjan C, Starlinger P.
PLoS One. 2015 Jan 22;10(1):e0116985. doi: 10.1371/journal.pone.0116985.
126. [Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.](#)
Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry R, Stiff J, Wrba F, **Gruenberger T**, Lenz HJ.
Cancer. 2015 Jun 1;121(11):1898-905. doi: 10.1002/cncr.29259.
127. [Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.](#)
Stremitzer S, Sunakawa Y, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry R, Stiff J, Wrba F, **Gruenberger T**,

- Lenz HJ.
Pharmacogenomics J. 2015 Dec;15(6):521-9. doi: 10.1038/tpj.2015.14.
128. [Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.](#)
Stremitzer S, Stiff J, Singh J, Starlinger P, Gruenberger B, Tamandl D, **Gruenberger T**.
Eur J Surg Oncol. 2015 Jul;41(7):868-74. doi: 10.1016/j.ejso.2015.03.223.
129. [Plasma thrombospondin 1 as a predictor of postoperative liver dysfunction.](#)
Starlinger P, Haegele S, Wanek D, Zikeli S, Schauer D, Alidzanovic L, Fleischmann E, Gruenberger B, **Gruenberger T**, Brostjan C.
Br J Surg. 2015 Jun;102(7):826-36. doi: 10.1002/bjs.9814.
130. [Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases.](#)
Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Sebio A, Yamauchi S, Matsusaka S, Parekh A, Barzi A, El-Khoueiry R, Stiff J, Wrba F, **Gruenberger T**, Lenz HJ.
Ann Oncol. 2015 Aug;26(8):1728-33. doi: 10.1093/annonc/mdv224.
131. [Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.](#)
Tanis E, Julié C, Emile JF, Mauer M, Nordlinger B, Aust D, Roth A, Lutz MP, **Gruenberger T**, Wrba F, Sorbye H, Bechstein W, Schlag P, Fisseler A, Ruers T.
Eur J Cancer. 2015 Nov;51(17):2708-17. doi: 10.1016/j.ejca.2015.08.014.
132. [Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.](#)
Pilat N, **Grünberger T**, Längle F, Mittlböck M, Perisanidis B, Kappel S, Wolf B, Starlinger P, Kühner I, Mühlbacher F, Kandioler D.
Eur J Surg Oncol. 2015 May;41(5):683-9. doi: 10.1016/j.ejso.2015.02.003.
133. [The Profile of Platelet \$\alpha\$ -Granule Released Molecules Affects](#)

[Postoperative Liver Regeneration.](#)

Starlinger P, Haegele S, Offensperger F, Oehlberger L, Pereyra D, Kral JB, Schrottmaier WC, Badrnya S, Reiberger T, Ferlitsch A, Stift J, Luf F, Brostjan C, **Gruenberger T**, Assinger A.

Hepatology. 2015 Nov 3. doi: 10.1002/hep.28331.

134. Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response
D. Schauer, **Th. Gruenberger**, C. Brostjan
Oncolmmunology; 2016 Mar 22;5(6):e1160185. doi:
10.1080/2162402X.2016.1160185. eCollection 2016 Jun. PMID: 27471631
135. Treatment sequence of synchronously (liver) metastasized colon cancer.
Gruenberger T, Beets G, Van Laethem JL, Rougier P, Cervantes A, Douillard JY, Figueras J, Gruenberger B, Haller DG, Labianca R, Maleux G, Roth A, Ducreux M, Schmiegel W, Seufferlein T, Van Cutsem E.
Dig Liver Dis. 2016 Oct;48(10):1119-23. doi: 10.1016/j.dld.2016.06.009.
Epub 2016 Jun 17.
136. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, **Gruenberger T**, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.
Ann Oncol. 2016 Aug;27(8):1386-422. doi:10.1093/annonc/mdw235.Epub 2016 Jul 5. PMID: 27380959
137. The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance.
Alidzanovic L, Starlinger P, Schauer D, Maier T, Feldman A, Buchberger E, Stift J, Koeck U, Pop L, Gruenberger B, **Gruenberger T**, Brostjan C.
Oncotarget. 2016 Aug 30;7(35):57197-57212. doi:10.18632/oncotarget.11084. PMID: 27527865

138. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer.
Jones RP, Malik HZ, Fenwick SW, Terlizzo M, O'Grady E, Stremitzer S, **Gruenberger T**, Rees M, Plant G, Figueras J, Albiol M, Adam R, Awad S, Poston GJ.
Eur J Surg Oncol. 2016 Dec;42(12):1866-1872. doi:10.1016/j.ejso.2016.07.142. Epub 2016 Aug 10. PMID: 27561844
139. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Valle JW, Borbath I, Khan SA, Huguet F, **Gruenberger T**, Arnold D; ESMO Guidelines Committee.
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37. No abstract available.
PMID: 27664259
140. Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection.
Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stiff J, Wrba F, **Gruenberger T**, Lenz HJ.
Mol Cancer Ther. 2016 Nov;15(11):2814-2821. Epub 2016 Aug 17.
PMID: 27535973
141. Perioperative Non-Invasive Indocyanine Green-Clearance Testing to Predict Postoperative Outcome after Liver Resection.
Haegele S, Reiter S, Wanek D, Offensperger F, Pereyra D, Stremitzer S, Fleischmann E, Brostjan C, **Gruenberger T**, Starlinger P.
PLoS One. 2016 Nov 3;11(11):e0165481. doi:10.1371/journal.pone.0165481. eCollection 2016. PMID: 27812143
142. Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity.
Pereyra D, Offensperger F, Klinglmueller F, Haegele S, Oehlberger L, **Gruenberger T**, Brostjan C, Starlinger P.
PLoS One. 2017 Apr 13;12(4):e0175359. doi: 10.1371/journal.pone.0175359. eCollection 2017. PMID: 28406940

143. Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients.
Adam R, Yi B, Innominato PF, Barroso E, Laurent C, Giuliante F, Capussotti L, Lapointe R, Regimbeau JM, Lopez-Ben S, Isoniemi H, Hubert C, Lin JK, **Gruenberger T**, Elias D, Skipenko OG, Guglielmi A; LiverMetSurvey International Contributing Centers.
Eur J Cancer. 2017 Jun;78:7-15. doi: 10.1016/j.ejca.2017.03.009. Epub 2017 Apr 10. PMID: 28407529
144. Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis.
Dengler M, Staufer K, Huber H, Stauber R, Bantel H, Weiss KH, Starlinger P, Pock H, Klöters-Plachky P, Gotthardt DN, Rauch P, Lackner C, Stiff J, Brostjan C, **Gruenberger T**, Kumada T, Toyoda H, Tada T, Weiss TS, Trauner M, Mikulits W.
Oncotarget. 2017 Jul 11;8(28):46234-46248. doi: 10.18632/oncotarget.17598. PMID: 28526812
145. Long-term outcomes of patients with 10 or more colorectal liver metastases.
Allard MA, Adam R, Giuliante F, Lapointe R, Hubert C, Ijzermans JNM, Mirza DF, Elias D, Laurent C, **Gruenberger T**, Poston G, Letoublon C, Isoniemi H, Lucidi V, Popescu I, Figueras J.
Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.218. [Epub ahead of print] PMID: 28728